Literature DB >> 21455598

Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids.

Mandeep S Saund1, Riad H Al Natour, Ashish M Sharma, Qin Huang, Valia A Boosalis, Jason S Gold.   

Abstract

BACKGROUND: Radical resection with regional lymphadenectomy is recommended for all sporadic gastric carcinoids. Local resection, however, is accepted for some carcinoids from other gastrointestinal sites (i.e., appendix and rectum). We sought to examine the relation of tumor size and depth to lymph node metastasis to determine whether gastric carcinoids can be selected for endoscopic resection. We also sought to quantify the utilization of lymph node sampling.
METHODS: 984 patients with localized gastric carcinoids who underwent cancer-directed surgery between 1983 and 2005 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry database.
RESULTS: Tumor size and depth predicted probability of lymph node metastasis. Lymph node metastasis was not seen in intraepithelial (IE) tumors <2 cm. Of tumors <1 cm invading into the lamina propria or submucosa (LP/SM), 3.4% had lymph node metastasis. Excluding IE tumors <2 cm and LP/SM tumors <1 cm, all other subgroups based on size and depth had rates of lymph node metastasis ≥ 8%. Tumor size and depth predicted probability of lymph node sampling. Overall, only 21% of tumors had lymph node sampling. Excluding IE tumors <2 cm and LP/SM tumors <1 cm, only 43% of tumors had lymph node sampling.
CONCLUSIONS: Tumor size and depth predict lymph node metastasis for gastric carcinoids. Endoscopic resection may be appropriate for intraepithelial (IE) tumors <2 cm and perhaps tumors <1 cm invading into the lamina propria or submucosa. Lymph node sampling is underused for gastric carcinoids at high risk for lymph node metastasis.

Entities:  

Mesh:

Year:  2011        PMID: 21455598     DOI: 10.1245/s10434-011-1652-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  29 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  Unfavorable effect of small tumor size on cause-specific survival in stage IIA colon cancer, a SEER-based study.

Authors:  Yuwei Wang; Changhua Zhuo; Debing Shi; Hongtu Zheng; Ye Xu; Weilie Gu; Sanjun Cai; Guoxiang Cai
Journal:  Int J Colorectal Dis       Date:  2014-11-13       Impact factor: 2.571

3.  Long-term follow up of endoscopic resection for type 3 gastric NET.

Authors:  Yong Hwan Kwon; Seong Woo Jeon; Gwang Ha Kim; Jin Il Kim; Il-Kwun Chung; Sam Ryong Jee; Heung Up Kim; Geom Seog Seo; Gwang Ho Baik; Kee Don Choi; Jeong Seop Moon
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

Review 4.  Endoscopic diagnosis and management of type I neuroendocrine tumors.

Authors:  Yuichi Sato
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 5.  Clinical features and management of type I gastric carcinoids.

Authors:  Yuichi Sato
Journal:  Clin J Gastroenterol       Date:  2014-09-17

6.  Management of gastric carcinoids (neuroendocrine neoplasms).

Authors:  Mark Kidd; Bjorn I Gustafsson
Journal:  Curr Gastroenterol Rep       Date:  2012-12

7.  Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.

Authors:  Katiuscha Merath; Fabio Bagante; Eliza W Beal; Alexandra G Lopez-Aguiar; George Poultsides; Eleftherios Makris; Flavio Rocha; Zaheer Kanji; Sharon Weber; Alexander Fisher; Ryan Fields; Bradley A Krasnick; Kamran Idrees; Paula M Smith; Cliff Cho; Megan Beems; Carl R Schmidt; Mary Dillhoff; Shishir K Maithel; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2018-02-15       Impact factor: 3.454

Review 8.  [Endoscopic therapy for gastroduodenal neuroendocrine neoplasms].

Authors:  S Maasberg; C Jürgensen; F Scheerer; R Pschowski; S Felder; N Begum; B Wiedenmann; A Pascher; U-F Pape
Journal:  Chirurg       Date:  2016-04       Impact factor: 0.955

9.  Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome.

Authors:  Andrew Hanna; Caroline Kim-Kiselak; Rebecca Tang; David C Metz; Zhaohai Yang; Ronald DeMatteo; Douglas L Fraker; Robert E Roses
Journal:  Ann Surg Oncol       Date:  2021-06-13       Impact factor: 5.344

10.  Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.

Authors:  Roberta Elisa Rossi; Pietro Invernizzi; Vincenzo Mazzaferro; Sara Massironi
Journal:  United European Gastroenterol J       Date:  2019-11-22       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.